Common Contracts
20 similar Loan Agreement contracts by Coherus BioSciences, Inc., Epizyme, Inc., Global Blood Therapeutics, Inc., others
II- 5.6. Compliance with Laws ................................................. ................................................................... 34 5.7. Protection of Intellectual Property Rights .......................................Loan Agreement • August 8th, 2024 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Standard Contracts
SECOND AMENDED AND RESTATED LOAN AGREEMENTLoan Agreement • July 29th, 2024 • New York
THIS SECOND AMENDED AND RESTATED LOAN AGREEMENT (this “Agreement”), dated as of July 28, 2024 (the “Effective Date”) by and among COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation (as “Borrower”), the Guarantors from time to time party hereto, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). This Agreement amends and restates in its entirety, and replaces, the terms of (and obligations outstanding under) that certain Amended and Resta
LOAN AGREEMENT Dated as of May 8, 2024 among COHERUS BIOSCIENCES, INC. (as Borrower, and a Credit Party), COHERUS INTERMEDIATE CORP. and INTEKRIN THERAPEUTICS INC. (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE...Loan Agreement • May 21st, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
THIS LOAN AGREEMENT (this “Agreement”), dated as of May 8, 2024 (the “Closing Date”) by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as “Borrower” and a Credit Party), COHERUS INTERMEDIATE CORP., a Delaware corporation (as an additional Credit Party), INTEKRIN THERAPEUTICS INC., a Delaware corporation (as an additional Credit Party), Surface Oncology, LLC, a Delaware limited liability company (as an additional Credit Party), Coherus Oncology Supportive Care LLC, a Delaware limited liability company (as an additional Credit Party) and the other Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, Ankura Trust Company, LLC, a New Hampshire limited liability company (as the administrative agent and collateral agent, “Collateral Agent”), each of the lenders signatory hereto (each, a “Lender”, and collectively, the “Lenders”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions
II- 5 AFFIRMATIVE COVENANTS ................................................... ................................................................ 34 5.1. Maintenance of Existence .........................................................Loan Agreement • May 2nd, 2024 • NovoCure LTD • Surgical & medical instruments & apparatus
AMENDED AND RESTATED LOAN AGREEMENT Dated as of March 13, 2024 among UROGEN PHARMA, INC. (as Borrower, and a Credit Party), UROGEN PHARMA LTD. (as Parent, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME...Loan Agreement • March 14th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
LOAN AGREEMENT Dated as of May 5, 2023 among REATA PHARMACEUTICALS, INC. (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral...Loan Agreement • May 10th, 2023 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
THIS LOAN AGREEMENT (this “Agreement”), dated as of May 5, 2023 (the “Effective Date”) by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. LOAN AGREEMENT Dated as...Loan Agreement • April 28th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations
THIS LOAN AGREEMENT (this “Agreement”), dated as of April 6, 2023 (the “Effective Date”) by and among IMMUNOGEN, INC., a Massachusetts corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENT Dated as of October 19, 2022 among INSMED INCORPORATED (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral...Loan Agreement • October 27th, 2022 • INSMED Inc • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of October 19, 2022 (the “Closing Date”) by and among INSMED INCORPORATED, a Virginia corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENT Dated as of March 7, 2022 among UROGEN PHARMA, INC. (as Borrower, and a Credit Party), UROGEN PHARMA LTD. (as Parent, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional...Loan Agreement • May 10th, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of March 7, 2022 (the “Effective Date”) by and among UROGEN PHARMA, INC., a Delaware corporation (as “Borrower” and a Credit Party), UROGEN PHARMA LTD., a company incorporated in Israel with company registration number 513537621 (as “Parent” and a Credit Party), the other Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extens
AMENDED AND RESTATED LOAN AGREEMENT Dated as of December 14, 2021 among GLOBAL BLOOD THERAPEUTICS, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR LIMITED PARTNERSHIP (as a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP...Loan Agreement • February 23rd, 2022 • Global Blood Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, pursuant to the Loan Agreement dated as of December 17, 2019 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Borrower, the Collateral Agent and the other parties thereto, Lenders agrees to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;
LOAN AGREEMENT Dated as of January 5, 2022 among COHERUS BIOSCIENCES, INC. (as Borrower, and a Credit Party), COHERUS INTERMEDIATE CORP. and INTEKRIN THERAPEUTICS INC. (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE...Loan Agreement • January 7th, 2022 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of January 5, 2022 (the “Effective Date”) by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as “Borrower” and a Credit Party), COHERUS INTERMEDIATE CORP., a Delaware corporation (as an additional Credit Party), INTEKRIN THERAPEUTICS INC., a Delaware corporation (as an additional Credit Party), the other Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall mak
LOAN AGREEMENT Dated as of December 14, 2021 among EVOLUS, INC. (as Borrower, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral...Loan Agreement • December 14th, 2021 • Evolus, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of December 14, 2021 (the “Effective Date”) by and among EVOLUS, INC., a Delaware corporation (as “Borrower” and a Credit Party), the other Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENT Dated as of March 23, 2021 among LUMIRADX INVESTMENT LIMITED (as Borrower, and a Credit Party), LUMIRADX GROUP LIMITED (as Parent, and a Credit Party), LUMIRADX LIMITED (as Issuer and a Credit Party), EACH OTHER GUARANTOR SIGNATORY...Loan Agreement • July 7th, 2021 • LumiraDx LTD • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of March 23, 2021 (the “Effective Date”) by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), LUMIRADX GROUP LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 09198288 (as “Parent” and a Credit Party), LUMIRADX LIMITED, an exempted company incorporated with limited liability in the Cayman Islands (registered number 314391) (as “Issuer” and a Credit Party), the other Guarantors signatory hereto or otherwise party hereto from time to time party hereto, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales wit
AMENDED AND RESTATED LOAN AGREEMENT Dated as of November 3, 2020Loan Agreement • February 23rd, 2021 • Epizyme, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED LOAN AGREEMENT (this “Agreement”), dated as of November 3, 2020 (the “Effective Date”) by and among EPIZYME, INC., a Delaware corporation (as “Borrower”), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership formed under the laws of England (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). Borrower, the Collateral Agent and BioPharma Credit Investments V (Master) LP are party to that certain Loan Agreement (the “Original Loan Agreement”), dated as of November 4, 2019 (the “Execution Date”). Borrower has requested that Lenders make available to Borrower the Tranche D Loan (as hereinafter defined) and, in connection with Lenders’ agreement to pr
LOAN AGREEMENTLoan Agreement • March 12th, 2020 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of November 11, 2019 (the “Effective Date”) by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (as an additional Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENT Dated as of November 4, 2019Loan Agreement • February 27th, 2020 • Epizyme, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of November 4, 2019 (the “Execution Date”) by and among EPIZYME, INC., a Delaware corporation (as “Borrower”), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENTLoan Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of December 13, 2019 (the “Effective Date”) by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), the Guarantors from time to time party hereto, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENT Dated as of December 17, 2019 among GLOBAL BLOOD THERAPEUTICS, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender)Loan Agreement • February 26th, 2020 • Global Blood Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, pursuant to the Loan Agreement dated as of December 17, 2019 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among Borrower, the Collateral Agent and the other parties thereto, Lenders agrees to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;
LOAN AGREEMENT Dated as of February 6, 2020Loan Agreement • February 10th, 2020 • Collegium Pharmaceutical, Inc • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of February 6, 2020 (the “Effective Date”) by and among COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation (as “Borrower”), the Guarantors from time to time party hereto, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
LOAN AGREEMENTLoan Agreement • February 28th, 2018 • TESARO, Inc. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of November 21, 2017 (the “Effective Date”) by and among TESARO, INC., a Delaware corporation (as “Borrower”), TESARO SECURITIES CORPORATION, a Massachusetts corporation (as an additional Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as “Collateral Agent” and a “Lender”) and BIOPHARMA CREDIT INVESTMENTS IV SUB LP, a Cayman Islands limited partnership (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
